Loading...
Organisme vivant modifié (LMO)
  |  
| 
Identité de l’organisme vivant modifié
L’image ci-dessous identifie l’OVM par son identificateur unique, son nom commercial et un lien vers cette page du Centre d’échange Cliquer dessus pour télécharger une plus grande image sur votre ordinateur Pour du soutien sur comment utiliser, aller dans la page de liens rapides OVM.
AviPro® Megan® Vac 1 vaccine
EN
AVIPRO MEGAN VAC 1
Non
AviPro® Megan® Vac 1 is a live attenuated veterinary vaccine intended to reduce colonization by Salmonella in chickens. The vaccine consists of a genetically modified strain of Salmonella enterica subsp. enterica serovar Typhimurium in which the cyaA and crp genes have been disrupted, resulting in attenuation of the bacterium while retaining its ability to induce a protective immune response. The vaccine helps reduce colonization by Salmonella Typhimurium, Salmonella Enteritidis and Salmonella Heidelberg in growing chickens.
EN
Le terme « organisme récepteur » désigne un organisme (non modifié ou déjà modifié) ayant fait l'objet d'une modification génétique, tandis que les « organismes parentaux » désignent les organismes impliqués dans un croisement ou une fusion cellulaire pour générer un organisme modifié.
FR
Caractéristiques du processus de modification
P22HTint
EN
  • Transgénèse par agrobacterium
Certains de ces éléments génétiques peuvent être présents sous forme de fragments ou sous forme tronquée. Veuillez consulter les notes ci-dessous, s’il y a lieu.
  • BCH-GENE-SCBD-301085-1 Adenylate cyclase | Salmonella typhimurium (SALTM)
    Séquence codante de protéines | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins)
  • BCH-GENE-SCBD-301086-1 cAMP-activated global transcriptional regulator CRP | Salmonella typhimurium (SALTM)
    Séquence codante de protéines | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins)
Information on the modified genetic elements

AviPro® Megan® Vac 1 is derived from Salmonella enterica subsp. enterica serovar Typhimurium strain UK-1 and is attenuated by mutations affecting the cyaA and crp genes. These mutations were generated using Tn10-mediated mutagenesis and bacteriophage P22 HT int-mediated transduction. The combined disruption of cyaA and crp interferes with cAMP-dependent regulation and contributes to attenuation of S. Typhimurium while retaining sufficient viability and immunogenicity for use as a live vaccine.

(1) cyaA gene

The cyaA gene encodes adenylate cyclase (CyaA), the enzyme responsible for the synthesis of cyclic adenosine monophosphate (cAMP). cAMP participates, together with the cAMP receptor protein (CRP), in the global regulation of numerous metabolic and physiological processes in Salmonella. During development of the attenuated strain, a Tn10-associated mutation affecting cyaA was transferred by generalized transduction using bacteriophage P22 HT int.  The resulting modification disrupts normal cyaA function and is commonly described as a Δcya or ΔcyaA mutation. More recent whole-genome sequence analysis of the commercial AviPro® Megan® Vac 1 strain confirmed disruption of cyaA, corresponding to locus STM3939 in the S. Typhimurium LT2 reference genome, and identified residual IS10-like sequence at the disrupted locus.

(2) crp gene

The crp gene encodes the cyclic AMP receptor protein (CRP), a global transcriptional regulator that interacts with cAMP and controls expression of numerous genes involved in bacterial metabolism and other cellular functions. A Tn10-associated mutation affecting crp was similarly introduced using P22 HT int-mediated generalized transduction, followed by selection of tetracycline-sensitive, fusaric-acid-resistant derivatives. The resulting modification disrupts normal crp function and is commonly described as a Δcrp mutation. Whole-genome sequence analysis of the commercial AviPro® Megan® Vac 1 strain confirmed disruption of crp, corresponding to locus STM3466 in the S. Typhimurium LT2 reference genome, and identified residual IS10-like sequence at the disrupted locus.

Note:
Bacteriophage P22 HT int was used as a generalized transducing phage during construction of the attenuated strain. It served as a vehicle for transferring Tn10-associated cyaA and crp mutations into the S. Typhimurium recipient background and was not intended to remain as an intact genetic element in the final vaccine strain.
Tn10 was used as part of the mutagenesis and selection procedure. The transposon contains IS10 elements associated with genes conferring tetracycline resistance. Following transduction and selection, tetracycline-sensitive derivatives were obtained using fusaric-acid selection. Therefore, the tetracycline-resistance phenotype associated with Tn10 was not retained in the final attenuated strain.
Whole-genome sequencing of the commercial AviPro® Megan® Vac 1 strain subsequently identified IS10-like sequences at both the disrupted cyaA and crp loci. The residual transposon-derived sequences were determined to be at least 1,329 bp in length; however, their exact length and complete organization could not be resolved using the available short-read sequencing data. Genes conferring tetracycline resistance were not detected.
EN
Caractéristiques de l’OVM
FR
  • Vaccin
Méthode(s) de détection
FR
Informations supplémentaires
FR